Compare Twist Bioscience Corp (TWST) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Zillow Group Inc Class C — how do they compare? Twist Bioscience Corp trades at $121.6 (market cap $7.72B), while Zillow Group Inc Class C trades at $33.1 (market cap $7.68B). The key difference: Twist Bioscience Corp and Zillow Group Inc Class C are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| TWST | Z | |
|---|---|---|
Market Cap | $7.72B | $7.68B |
Sector | Health | Media |
52-Week High | $124.88 | $90.35 |
52-Week Low | $24.16 | $29.41 |
Enterprise Value | $7.65B | $7.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Zillow Group (Z) trades at $33.48, down 0.8% on the day, amid mixed technical signals and ongoing securities litigation. The company shows improving fundamentals with Q2 2026 revenue growth of 18% and consecutive earnings beats, though net margins remain thin at 1.96%. Analyst consensus is divided with a $52 price target representing 55% upside potential from current levels.
While Zillow demonstrates operational improvement and strong monetization growth, significant headwinds include multiple class-action lawsuits and bearish technical indicators. The stock offers substantial upside if legal concerns resolve favorably, but near-term volatility persists due to legal overhang and competitive real estate market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
